<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006865.pub2" GROUP_ID="SYMPT" ID="614704081311273751" MERGED_FROM="" MODIFIED="2017-07-24 12:27:31 +0100" MODIFIED_BY="Anna Erskine" REVIEW_NO="121" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2017-07-24 12:26:47 +0100" MODIFIED_BY="Anna Erskine">
<TITLE MODIFIED="2010-03-05 11:26:52 +0000" MODIFIED_BY="[Empty name]">Single dose oral lumiracoxib for postoperative pain in adults</TITLE>
<CONTACT>
<PERSON ID="12205" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Yvonne</FIRST_NAME>
<MIDDLE_INITIALS>M</MIDDLE_INITIALS>
<LAST_NAME>Roy</LAST_NAME>
<SUFFIX/>
<POSITION>Assistant Managing Editor</POSITION>
<EMAIL_1>yvonneroy66@yahoo.com</EMAIL_1>
<EMAIL_2/>
<URL>www.jr2.ox.ac.uk/Cochrane</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cochrane Pain, Palliative and Supportive Care Group</DEPARTMENT>
<ORGANISATION>Pain Research Unit</ORGANISATION>
<ADDRESS_1>The Churchill Hospital</ADDRESS_1>
<ADDRESS_2>Old Road</ADDRESS_2>
<CITY>Oxford</CITY>
<ZIP>OX3 7LE</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 1865 225775</PHONE_1>
<PHONE_2/>
<FAX_1>+44 1865 225400</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2017-07-24 12:26:47 +0100" MODIFIED_BY="Anna Erskine">
<PERSON ID="12205" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Yvonne</FIRST_NAME>
<MIDDLE_INITIALS>M</MIDDLE_INITIALS>
<LAST_NAME>Roy</LAST_NAME>
<SUFFIX/>
<POSITION>Assistant Managing Editor</POSITION>
<EMAIL_1>yvonneroy66@yahoo.com</EMAIL_1>
<EMAIL_2/>
<URL>www.jr2.ox.ac.uk/Cochrane</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cochrane Pain, Palliative and Supportive Care Group</DEPARTMENT>
<ORGANISATION>Pain Research Unit</ORGANISATION>
<ADDRESS_1>The Churchill Hospital</ADDRESS_1>
<ADDRESS_2>Old Road</ADDRESS_2>
<CITY>Oxford</CITY>
<ZIP>OX3 7LE</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 1865 225775</PHONE_1>
<PHONE_2/>
<FAX_1>+44 1865 225400</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5475F46C82E26AA20187B79619319C6E" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Sheena</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Derry</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Research Officer</POSITION>
<EMAIL_1>sheena.derry@ndcn.ox.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Pain Research and Nuffield Department of Clinical Neurosciences (Nuffield Division of Anaesthetics)</DEPARTMENT>
<ORGANISATION>University of Oxford</ORGANISATION>
<ADDRESS_1>Pain Research Unit</ADDRESS_1>
<ADDRESS_2>Churchill Hospital</ADDRESS_2>
<CITY>Oxford</CITY>
<ZIP>OX3 7LE</ZIP>
<REGION>Oxfordshire</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 1865 225405</PHONE_1>
<PHONE_2/>
<FAX_1>+44 1865 225402</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="7899" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>R Andrew</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Moore</LAST_NAME>
<SUFFIX>DSc</SUFFIX>
<POSITION>Research Director</POSITION>
<EMAIL_1>andrew.moore@ndcn.ox.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Pain Research and Nuffield Department of Clinical Neurosciences (Nuffield Division of Anaesthetics)</DEPARTMENT>
<ORGANISATION>University of Oxford</ORGANISATION>
<ADDRESS_1>Pain Research Unit</ADDRESS_1>
<ADDRESS_2>Churchill Hospital</ADDRESS_2>
<CITY>Oxford</CITY>
<ZIP>OX3 7LE</ZIP>
<REGION>Oxfordshire</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 1865 225401</PHONE_1>
<PHONE_2/>
<FAX_1>+44 1865 225402</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2012-04-25 15:34:38 +0100" MODIFIED_BY="Jessica Thomas">
<UP_TO_DATE>
<DATE DAY="5" MONTH="3" YEAR="2010"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="5" MONTH="3" YEAR="2010"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="3" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="" YEAR=""/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2007"/>
<LAST_CITATION_ISSUE ISSUE="7" YEAR="2010"/>
</DATES>
<WHATS_NEW MODIFIED="2017-07-19 16:38:30 +0100" MODIFIED_BY="Anna Erskine">
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2017-07-19 16:38:30 +0100" MODIFIED_BY="Anna Erskine">
<DATE DAY="19" MONTH="7" YEAR="2017"/>
<DESCRIPTION>
<P>See <LINK TAG="PUBLIC_NOTES" TYPE="SECTION">Published notes</LINK>.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2017-07-19 16:38:16 +0100" MODIFIED_BY="Anna Erskine">
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2017-07-19 16:38:16 +0100" MODIFIED_BY="Anna Erskine">
<DATE DAY="25" MONTH="4" YEAR="2012"/>
<DESCRIPTION>
<P>The authors have checked the literature in 2012 and believe it unlikely there will be any new additional studies to include in this review for at least five years.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-04-25 15:34:57 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="17" MONTH="6" YEAR="2010"/>
<DESCRIPTION>
<P>New search February 2010</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2012-04-25 15:35:01 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="5" MONTH="3" YEAR="2010"/>
<DESCRIPTION>
<P>One new study identified and included in analyses, increasing number of participants treated with lumiracoxib 400 mg by 73%. Conclusions are unchanged, but confidence in results is increased.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-06-15 13:39:12 +0100" MODIFIED_BY="Caroline Struthers">
<DATE DAY="7" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Minor change to in-house referencing code</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-11-07 13:06:41 +0000" MODIFIED_BY="Jessica R Thomas">
<DATE DAY="6" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-07-29 15:55:47 +0100" MODIFIED_BY="Jessica R Thomas">
<DATE DAY="24" MONTH="1" YEAR="2008"/>
<DESCRIPTION>
<P>On November 2007 the UK Medicines and Healthcare Regulatory Authority suspended the marketing authorisation for Lumiracoxib following safety concerns relating to liver damage in patients prescribed the drug for chronic/long term condiions such as osteoarthritis.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2010-02-18 14:19:32 +0000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Oxford Pain Relief Trust</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2010-02-18 14:19:32 +0000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2010-02-18 14:19:04 +0000" MODIFIED_BY="[Empty name]">
<NAME>NHS Cochrane Collaboration Grant</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2010-02-18 14:19:32 +0000" MODIFIED_BY="[Empty name]">
<NAME>NIHR Biomedical Research Centre Programme</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2017-07-24 12:26:59 +0100" MODIFIED_BY="Anna Erskine">
<SUMMARY MODIFIED="2010-06-15 13:40:33 +0100" MODIFIED_BY="Caroline Struthers">
<TITLE MODIFIED="2010-02-18 15:51:39 +0000" MODIFIED_BY="[Empty name]">Single dose oral lumiracoxib (Prexige®) for acute postoperative pain relief in adults</TITLE>
<SUMMARY_BODY MODIFIED="2010-06-15 13:40:33 +0100" MODIFIED_BY="Caroline Struthers">
<P>Postoperative pain is often poorly managed. Cyclooxygenase inhibitors (COX-2) pain relieving drugs were developed with the aim of reducing the gastrointestinal side effects of non-steroidal anti-inflammatory drugs (NSAIDs). Lumiracoxib 400 mg provided rapid, effective, and sustained relief of postoperative pain in four studies in dental and orthopaedic surgery. Of 366 participants treated with lumiracoxib 400 mg half experienced a high level of pain relief (at least 50% pain relief over a six hour period), compared with 8% given placebo. The duration of analgesia was relatively long at 9 hours, and fewer participants needed to use rescue medication with lumiracoxib than with placebo. Adverse event data was inconsistently reported, but no serious adverse events occurred in any patient taking lumiracoxib in these studies.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2010-06-15 13:39:53 +0100" MODIFIED_BY="Caroline Struthers">
<ABS_BACKGROUND MODIFIED="2010-02-18 15:58:48 +0000" MODIFIED_BY="[Empty name]">
<P>Lumiracoxib is a selective cyclooxygenase-2 (COX-2) inhibitor. COX-2 inhibitors were developed to avoid COX-1-related gastrointestinal (GI) problems while maintaining the analgesic and anti-inflammatory activity of traditional non-steriodal anti-inflammatory drugs (NSAIDs).</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2010-02-18 16:02:58 +0000" MODIFIED_BY="[Empty name]">
<P>To review the analgesic efficacy, duration of analgesia<B>, </B>and adverse effects of a single oral dose of lumiracoxib for moderate to severe postoperative pain in adults.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2010-02-18 15:38:52 +0000" MODIFIED_BY="[Empty name]">
<P>We searched Cochrane CENTRAL, MEDLINE, and EMBASE to February 2010.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2010-02-18 15:40:14 +0000" MODIFIED_BY="[Empty name]">
<P>Single oral dose, randomised, double-blind, placebo-controlled trials of lumiracoxib for relief of established moderate to severe postoperative pain in adults.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2010-02-18 15:41:00 +0000" MODIFIED_BY="[Empty name]">
<P>Studies were assessed for methodological quality and the data extracted by two review authors independently. Summed total pain relief over six hours (TOTPAR 6) was used to calculate the number of participants achieving at least 50% pain relief. These derived results were used to calculate, with 95% confidence intervals, the relative benefit compared to placebo, and the number needed to treat (NNT) for one participant to experience at least 50% pain relief over six hours. Numbers of participants using rescue medication, and time to use of rescue medication, were sought as additional measures of efficacy. Information on adverse events and withdrawals was collected.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2010-06-15 13:39:53 +0100" MODIFIED_BY="Caroline Struthers">
<P>In this updated review four studies met the inclusion criteria. In total 366 participants were treated with lumiracoxib 400 mg, 51 with lumiracoxib 100 mg, and 212 with placebo. Active comparators were naproxen 500 mg, rofecoxib 50 mg, celecoxib 200 mg, celecoxib 400 mg, and ibuprofen 400 mg. With lumiracoxib 400 mg 50% of participants had at least 50% pain relief over six hours, compared with 8% given placebo; RB 6.9 (95% CI 4.1 to 12), NNT 2.4 (2.1 to 2.8).</P>
<P>Median time to onset of analgesia was shorter for lumiracoxib 400 mg (0.6 to 1.5 hours) than placebo (&gt;12 hours). Fewer participants needed rescue medication with lumiracoxib (64%) than with placebo (91%) over 12 to 24 hours; NNT to prevent remedication 3.7 (2.9 to 5.0). The weighted median time to use of rescue medication was 9.4 hours for lumiracoxib 400 mg and 1.7 hours for placebo.</P>
<P>Adverse events were generally mild to moderate in severity, with one serious event reported in a placebo patient.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2010-02-18 16:02:26 +0000" MODIFIED_BY="[Empty name]">
<P>Lumiracoxib 400 mg given as a single oral dose is an effective analgesic for acute postoperative pain, and has a relatively long duration of action. Adverse events with lumiracoxib did not differ from placebo.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2010-06-15 14:03:18 +0100" MODIFIED_BY="Caroline Struthers">
<BACKGROUND MODIFIED="2010-06-15 13:44:26 +0100" MODIFIED_BY="Caroline Struthers">
<P>This is an update of Single dose lumiracoxib for acute postoperative pain, published in <I>The Cochrane Library </I>in Issue 4, 2007 (<LINK REF="REF-Roy-2007" TYPE="REFERENCE">Roy 2007</LINK>). The title has been changed to reflect that the review considered only studies in adults.</P>
<P>Acute pain occurs as a result of tissue damage either accidentally due to an injury or as a result of surgery. Acute postoperative pain is a manifestation of inflammation due to tissue injury. The management of postoperative pain and inflammation is a critical component of patient care.<BR/>
<BR/>This is one of a series of reviews whose aim is to increase awareness of the range of analgesics that are potentially available, and present evidence for relative analgesic efficacy through indirect comparisons with placebo, in very similar trials performed in a standard manner, with very similar outcomes, and over the same duration. Such relative analgesic efficacy does not in itself determine choice of drug for any situation or patient, but guides policy-making at the local level. The series includes well established analgesics such as paracetamol (<LINK REF="REF-Toms-2008" TYPE="REFERENCE">Toms 2008</LINK>), naproxen (<LINK REF="REF-Derry-C-2009a" TYPE="REFERENCE">Derry C 2009a</LINK>), diclofenac (<LINK REF="REF-Derry-P-2009" TYPE="REFERENCE">Derry P 2009</LINK>), and ibuprofen (<LINK REF="REF-Derry-C-2009b" TYPE="REFERENCE">Derry C 2009b</LINK>), newer cyclo-oxygenase-2 selective analgesics, such as celecoxib (<LINK REF="REF-Derry-2008" TYPE="REFERENCE">Derry 2008</LINK>), etoricoxib (<LINK REF="REF-Clarke-2009" TYPE="REFERENCE">Clarke 2009</LINK>), and parecoxib (<LINK REF="REF-Lloyd-2009" TYPE="REFERENCE">Lloyd 2009</LINK>), and opioid/paracetamol combinations, such as paracetamol and codeine (<LINK REF="REF-Toms-2009" TYPE="REFERENCE">Toms 2009</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">Acute pain trials</HEADING>
<P>Single dose trials in acute pain are commonly short in duration, rarely lasting longer than 12 hours. The numbers of participants are small, allowing no reliable conclusions to be drawn about safety. To show that the analgesic is working, it is necessary to use placebo (<LINK REF="REF-McQuay-2005" TYPE="REFERENCE">McQuay 2005</LINK>). There are clear ethical considerations in doing this. These ethical considerations are answered by using acute pain situations where the pain is expected to go away, and by providing additional analgesia, commonly called rescue analgesia, if the pain has not diminished after about an hour. This is reasonable, because not all participants given an analgesic will have significant pain relief. Approximately 18% of participants given placebo will have significant pain relief (<LINK REF="REF-Moore-2006" TYPE="REFERENCE">Moore 2006</LINK>), and up to 50% may have inadequate analgesia with active medicines. The use of additional or rescue analgesia is hence important for all participants in the trials.<BR/>
<BR/>Clinical trials measuring the efficacy of analgesics in acute pain have been standardised over many years. Trials have to be randomised and double blind. Typically, in the first few hours or days after an operation, patients develop pain that is moderate to severe in intensity, and will then be given the test analgesic or placebo. Pain is measured using standard pain intensity scales immediately before the intervention, and then using pain intensity and pain relief scales over the following 4 to 6 hours for shorter acting drugs, and up to 12 or 24 hours for longer acting drugs. Pain relief of half the maximum possible pain relief or better (at least 50% pain relief) is typically regarded as a clinically useful outcome. For patients given rescue medication it is usual for no additional pain measurements to be made, and for all subsequent measures to be recorded as initial pain intensity or baseline (zero) pain relief (baseline observation carried forward). This process ensures that analgesia from the rescue medication is not wrongly ascribed to the test intervention. In some trials the last observation is carried forward, which gives an inflated response for the test intervention compared to placebo, but the effect has been shown to be negligible over 4 to 6 hours (<LINK REF="REF-Moore-2005a" TYPE="REFERENCE">Moore 2005a</LINK>). Patients usually remain in the hospital or clinic for at least the first 6 hours following the intervention, with measurements supervised, although they may then be allowed home to make their own measurements in trials of longer duration.</P>
<P>NSAIDs have pain-relieving, antipyretic and anti-inflammatory properties, and have proven efficacy following day surgery and minor surgery. They reversibly inhibit cyclooxygenase (prostaglandin endoperoxide synthase), the enzyme mediating production of prostaglandins (PGs) and thromboxane A2 (<LINK REF="REF-Fitzgerald-2001" TYPE="REFERENCE">Fitzgerald 2001</LINK>; <LINK REF="REF-Hawkey-1999" TYPE="REFERENCE">Hawkey 1999</LINK>). A major concern regarding the use of traditional NSAIDs, such as ibuprofen, naproxen and diclofenac, postoperatively is the possibility of bleeding from both the operative site (because of the inhibition of platelet aggregation) (<LINK REF="REF-Forrest-2002" TYPE="REFERENCE">Forrest 2002</LINK>) and from the upper gastrointestinal tract, (especially in patients stressed by surgery, the elderly, frail, or dehydrated). Drug treatments that combine the pain-relieving properties of NSAIDs without these adverse effects are likely to have a place in clinical practice.</P>
<P>Selective cyclo-oxygenase-2 (COX-2) inhibitors were developed to address the problem of upper gastrointestinal bleeding (<LINK REF="REF-Hawkey-2001" TYPE="REFERENCE">Hawkey 2001</LINK>). NSAIDs are thought to relieve pain by inhibiting cyclo-oxygenases and thus the production of prostaglandins. Prostaglandins occur throughout body tissues and fluids and act to stimulate pain nerve endings and promote/inhibit the aggregation of blood platelets. Cyclo-oxygenase has at least two isoforms: COX-1 and COX-2. COX-1 is constitutive while COX-2 is induced at sites of inflammation and produces the prostaglandins involved in inflammatory responses and pain mediation (<LINK REF="REF-Grahame_x002d_Smith-2002" TYPE="REFERENCE">Grahame-Smith 2002</LINK>). Unlike traditional NSAIDs, COX-2 inhibitors block primarily the action of COX-2 and cause fewer gastrointestinal effects (<LINK REF="REF-Moore-2005b" TYPE="REFERENCE">Moore 2005b</LINK>). In common with other NSAIDs, COX-2 inhibitors can give rise to fluid retention and renal damage (<LINK REF="REF-Garner-2002" TYPE="REFERENCE">Garner 2002</LINK>), so particular caution is needed in the elderly (<LINK REF="REF-Hawkey-2001" TYPE="REFERENCE">Hawkey 2001</LINK>). They have also been associated with increased cardiovascular problems, mainly in trials in patients with pre-cancerous colorectal polyps. (<LINK REF="REF-Kearney-2006" TYPE="REFERENCE">Kearney 2006</LINK>; <LINK REF="REF-Patrono-2009" TYPE="REFERENCE">Patrono 2009</LINK>). Use of coxibs and non-selective NSAIDs in patients with bowel problems such as ulcerative colitis and Crohn's Disease is complicated (<LINK REF="REF-Hawkey-2006" TYPE="REFERENCE">Hawkey 2006</LINK>).</P>
<P>Lumiracoxib (Prexige®) is a novel selective COX-2 inhibitor with claimed improved biochemical selectivity over that of currently available coxibs (<LINK REF="REF-Mysler-2004" TYPE="REFERENCE">Mysler 2004</LINK>). It is structurally distinct from other COX-2 selective inhibitors in that it has mildly acidic properties (<I>pKa </I>4.7). This acidity may be the reason for its distinct pharmacokinetic and pharmacodynamic profile, as weak acids have been shown to be readily sequestered into acidic environments such as inflamed joints (<LINK REF="REF-Day-1988" TYPE="REFERENCE">Day 1988</LINK>). It is used for the symptomatic relief of osteoarthritis at 100 to 200 mg/day with clinical efficacy similar to that of diclofenac 150 mg/day and celecoxib 200 mg/day. Patients with rheumatoid arthritis benefit from a daily dose of 200 to 400 mg daily. Furthermore, it has been found to be effective for acute pain associated with primary dysmenorrhoea, dental surgery and orthopaedic surgery, at a dose of 400 mg daily (<LINK REF="REF-Bannwarth-2005" TYPE="REFERENCE">Bannwarth 2005</LINK>). Lumiracoxib is believed to be as effective as traditional NSAIDs but is thought to have superior gastrointestinal safety, especially in the reduction of ulcer complications (<LINK REF="REF-Schnitzer-2004a" TYPE="REFERENCE">Schnitzer 2004a</LINK>). In 2007 lumiracoxib was withdrawn from the Australian market because of concerns about liver damage, and a number of other countries have since withdrawn it. Lumiracoxib has never been licensed in the USA, but is available in some countries in south and central America.</P>
<P>Since the original review was published in 2007, another relevant study has been published (previously in "ongoing studies"). Inclusion of this study in the review substantially increases the number of participants treated with lumiracoxib, providing more confidence in the results.<BR/>
</P>
</SUBSECTION>
</BACKGROUND>
<OBJECTIVES MODIFIED="2010-02-18 17:29:22 +0000" MODIFIED_BY="[Empty name]">
<P>To evaluate the analgesic efficacy and safety of lumiracoxib in the treatment of acute postoperative pain, using methods that permit comparison with other analgesics evaluated in the same way, and criteria of efficacy recommended by an in-depth study at the individual patient level (<LINK REF="REF-Moore-2005a" TYPE="REFERENCE">Moore 2005a</LINK>).</P>
</OBJECTIVES>
<METHODS MODIFIED="2010-06-15 13:53:30 +0100" MODIFIED_BY="Caroline Struthers">
<SELECTION_CRITERIA MODIFIED="2010-02-18 09:18:29 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2010-02-18 09:17:17 +0000" MODIFIED_BY="[Empty name]">
<P>Reports were included if they were published randomised placebo controlled, double blind trials of a single oral dose of lumiracoxib, with a minimum of 10 participants per treatment arm. Multiple dose studies were included if appropriate data from the first dose were available, and cross-over studies were included provided that data from the first arm were presented separately.</P>
<P>Abstracts, review articles, case reports, and clinical observations were excluded, as were reports that did not clearly state that the interventions had been randomly allocated, were concerned with other pain conditions, or used experimental pain or volunteer participants, or both.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2010-02-18 09:16:38 +0000" MODIFIED_BY="[Empty name]">
<P>Male or female patients (aged 15 years and above) experiencing postoperative pain of moderate to severe intensity, which is defined as &#8805;3 on a 4 point categorical scale or &#8805;30 mm on a 100 mm Visual Analogue Scale (VAS).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2010-02-18 09:16:35 +0000" MODIFIED_BY="[Empty name]">
<P>Single dose oral lumiracoxib or placebo administered postoperatively when pain intensity was moderate or severe.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2010-02-18 09:18:29 +0000" MODIFIED_BY="[Empty name]">
<P>Data were collected on the following outcomes:<BR/>
</P>
<UL>
<LI>patient characteristics;</LI>
<LI>pain model (dental or other type of surgery);</LI>
<LI>patient reported pain at baseline (physician, nurse, or carer reported pain will not be included in the analysis);</LI>
<LI>Patient-reported pain relief and/or pain intensity expressed hourly over four to six hours using validated pain scales (pain intensity and pain relief in the form of visual analogue scales (VAS) or categorical scales, or both), or reported total pain relief (TOTPAR) or summed pain intensity difference (SPID) at four to six hours;</LI>
<LI>number of participants using rescue medication;</LI>
<LI>time to use of rescue medication, and the time of assessment;</LI>
<LI>withdrawals - all cause, adverse event;</LI>
<LI>adverse events - participants experiencing one or more, and any serious adverse event, and the time of assessment.</LI>
</UL>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2010-06-15 13:53:30 +0100" MODIFIED_BY="Caroline Struthers">
<P>We searched the following databases:</P>
<UL>
<LI>Cochrane CENTRAL, Issue 1 2006 for the original review and March 2010 for the update;</LI>
<LI>MEDLINE (via OVID), 1966 to February 2007 for the original review and March 2010 for the update;</LI>
<LI>EMBASE (via OVID), 1974 to February 2007 for the original review and March 2010 for the update;</LI>
<LI>PaPaS Trials Register, February 2007 for the original review and March 2010 for the update </LI>
</UL>
<P>Reference lists of retrieved studies were also manually searched.</P>
<P>Search strategies for MEDLINE, EMBASE and CENTRAL can be found in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>, <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> and <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK> respectively.</P>
<SUBSECTION>
<HEADING LEVEL="3">Language</HEADING>
<P>No language restriction was applied.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Additional sources</HEADING>
<P>For the original review, authors of the included studies were contacted for additional numerical data, but none was supplied. The manufacturer of lumiracoxib (Norvatis Pharmaceuticals Corporation) was also contacted for further published or unpublished trials and abstracts. They provided information on two new ongoing trials, and also supplied additional data for the included studies. One of the ongoing trials has been published and is now included in this update. We are unable to find the other trial, but it may be a study comparing pre- and postoperative administration of lumiracoxib in knee arthroscopy, which would not qualify for inclusion in this review.</P>
<P>No further unpublished studies were identified in www.clinicaltrials.gov for the update.</P>
</SUBSECTION>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2010-03-04 16:33:12 +0000" MODIFIED_BY="[Empty name]">
<P>Two review authors independently carried out searches, reviewed the titles and abstracts retrieved, and agreed upon the reports that would be retrieved in full for assessment for inclusion in the review. Disagreements were resolved by discussion with the third author.</P>
<SUBSECTION>
<HEADING LEVEL="3">Quality Assessment</HEADING>
<P>Two review authors independently assessed the included studies for quality using a five-point scale (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>).</P>
<P>The scale used is as follows:<BR/>Is the study randomised? If yes - one point;<BR/>Is the randomisation procedure reported and is it appropriate? If yes add one point, if no deduct one point;<BR/>Is the study double blind? If yes then add one point;<BR/>Is the double blind method reported and is it appropriate? If yes add 1 point, if no deduct one point;<BR/>Are the reasons for patient withdrawals and dropouts described? If yes add one point.</P>
<P>A Risk of bias table was completed for the categories of randomisation, allocation concealment and blinding.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data management</HEADING>
<P>Data were extracted by two of the review authors and recorded on a standard data extraction form. Data suitable for pooling were entered into RevMan 5.0.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data analysis</HEADING>
<P>QUOROM guidelines were followed where appropriate (<LINK REF="REF-Moher-1999" TYPE="REFERENCE">Moher 1999</LINK>). For efficacy analyses we used the number of participants in each treatment group who were randomised, received medication, and provided at least one post-baseline assessment. For safety analyses we used number of participants randomised to each treatment group. Analyses were planned for different doses (where there were at least 200 participants). Sensitivity analyses were planned for pain model (dental versus other postoperative pain), trial size (39 or fewer versus 40 or more per treatment arm), and quality score (2 versus 3 or more).</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome: Number of participants achieving at least 50% pain relief</HEADING>
<P>For each study, mean TOTPAR (total pain relief) or SPID (summed pain intensity difference) for active and placebo groups were converted to %maxTOTPAR or %maxSPID by division into the calculated maximum value (<LINK REF="REF-Cooper-1991" TYPE="REFERENCE">Cooper 1991</LINK>). The proportion of participants in each treatment group who achieved at least 50%maxTOTPAR was calculated using verified equations (<LINK REF="REF-Moore-1996" TYPE="REFERENCE">Moore 1996</LINK>; <LINK REF="REF-Moore-1997a" TYPE="REFERENCE">Moore 1997a</LINK>; <LINK REF="REF-Moore-1997b" TYPE="REFERENCE">Moore 1997b</LINK>). These proportions were then converted into the number of participants achieving at least 50%maxTOTPAR by multiplying by the total number of participants in the treatment group. Information on the number of participants with at least 50%maxTOTPAR for active treatment and placebo was then used to calculate relative benefit (RR) and number needed to treat to benefit (NNT).</P>
<P>Pain measures accepted for the calculation of TOTPAR or SPID were:<BR/>
</P>
<UL>
<LI>five-point categorical pain relief (PR) scales with comparable wording to "none, slight, moderate, good or complete";</LI>
<LI>four-point categorical pain intensity (PI) scales with comparable wording to "none, mild, moderate, severe";</LI>
<LI>Visual analogue scales (VAS) for pain relief;</LI>
<LI>VAS for pain intensity;</LI>
<LI>five-point categorical global scale with the wording "poor, fair, good, very good, excellent" (<LINK REF="REF-Collins-2001" TYPE="REFERENCE">Collins 2001</LINK>).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes:</HEADING>
<P>
<B>1. Use of rescue medication</B>. Numbers of participants requiring rescue medication were used to calculate NNTs to prevent use of rescue medication for treatment and placebo groups. Median (or mean) time to use of rescue medication was used to calculate the weighted mean of the median (or mean) for the outcome. Weighting was by number of participants.</P>
<P>
<B>2. Adverse events.</B>
 Numbers of participants reporting adverse events for each treatment group were used to calculate relative risk (RR) and numbers needed to treat to harm (NNH) estimates for:<BR/>
</P>
<UL>
<LI>any adverse event</LI>
<LI>any serious adverse event (as reported in the study)</LI>
<LI>withdrawal due to an adverse event</LI>
</UL>
<P>
<B>3. Other withdrawals.</B> Withdrawals for reasons other than lack of efficacy (participants using rescue medication - see above) and adverse events were noted.</P>
<P>Relative benefit or risk estimates were calculated with 95% confidence intervals (CI) using a fixed-effect model (<LINK REF="REF-Morris-1995" TYPE="REFERENCE">Morris 1995</LINK>). NNT or NNH with 95% CI were calculated using the pooled number of events by the method of Cook and Sackett (<LINK REF="REF-Cook-1995" TYPE="REFERENCE">Cook 1995</LINK>). A statistically significant difference from control was assumed when the 95% CI of the relative benefit did not include one.</P>
<P>Homogeneity of studies was assessed visually (<LINK REF="REF-L_x0027_Abbe-1987" TYPE="REFERENCE">L'Abbe 1987</LINK>). The z test (<LINK REF="REF-Tramer-1997" TYPE="REFERENCE">Tramer 1997</LINK>) would be used to determine if there was a significant difference between NNTs for different doses of active treatment, or between groups in the sensitivity analyses.</P>
</SUBSECTION>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2010-06-15 13:59:28 +0100" MODIFIED_BY="Caroline Struthers">
<STUDY_DESCRIPTION MODIFIED="2010-06-15 13:59:28 +0100" MODIFIED_BY="Caroline Struthers">
<P>Searches for the original review identified five studies, and updated searches identified one more. Of these, four studies met the inclusion criteria and were included in the review (<LINK REF="STD-Chan-2005" TYPE="STUDY">Chan 2005</LINK>; <LINK REF="STD-Fricke-2008" TYPE="STUDY">Fricke 2008</LINK>; <LINK REF="STD-Kellstein-2004" TYPE="STUDY">Kellstein 2004</LINK>; <LINK REF="STD-Zelenakas-2004" TYPE="STUDY">Zelenakas 2004</LINK>). All studies were funded by Novartis Pharmaceuticals, the manufacturer of lumiracoxib, and were identified as potential randomised controlled trials (RCTs) that assessed the effectiveness of lumiracoxib 400 mg in acute postoperative pain compared to placebo. The other two studies were not in postoperative pain and were excluded. The study by <LINK REF="STD-Bitner-2004" TYPE="STUDY">Bitner 2004</LINK> was a study on the treatment of primary dysmenorrhoea and the study by <LINK REF="STD-Schnitzer-2004" TYPE="STUDY">Schnitzer 2004</LINK> was in patients with knee or hip primary osteoarthritis.</P>
<P>
<LINK REF="STD-Chan-2005" TYPE="STUDY">Chan 2005</LINK> studied postoperative total knee or hip arthroplasty patients with moderate to severe pain. One hundred and eighty patients were recruited, 60 patients received 400 mg single dose lumiracoxib, 60 received 500 mg naproxen, and 60 received placebo.</P>
<P>
<LINK REF="STD-Fricke-2008" TYPE="STUDY">Fricke 2008</LINK> studied postoperative dental patients, with third molar extractions who had moderate to severe pain. Three hundred and sixty-four participants were recruited: 156 received lumiracoxib 400 mg, 156 received celecoxib 400 mg, and 52 received placebo.</P>
<P>
<LINK REF="STD-Kellstein-2004" TYPE="STUDY">Kellstein 2004</LINK> was also a postoperative dental surgery study, of third molar extraction for patients with moderate to severe pain. Three hundred and fifty five patients were recruited, 101 received lumiracoxib 400 mg, 102 received rofecoxib 50 mg, 101 received celecoxib 200 mg and 51 received placebo.</P>
<P>
<LINK REF="STD-Zelenakas-2004" TYPE="STUDY">Zelenakas 2004</LINK> was another postoperative dental surgery study, of third molar extraction for patients with moderate to severe pain. Two hundred and two patients were recruited. Fifty received lumiracoxib 400 mg, and 51 received lumiracoxib 100 mg, 51 received ibuprofen 400 mg and 50 received placebo.</P>
<P>All studies used a single dose of study medication, or single dose phase, and all used a parallel group design. One study lasted for 12 hours (<LINK REF="STD-Zelenakas-2004" TYPE="STUDY">Zelenakas 2004</LINK>), and two (<LINK REF="STD-Fricke-2008" TYPE="STUDY">Fricke 2008</LINK>, <LINK REF="STD-Kellstein-2004" TYPE="STUDY">Kellstein 2004</LINK>) for 24 hours, and one had a 12 hour single dose phase followed by a multiple dose phase lasting up to 96 hours (<LINK REF="STD-Chan-2005" TYPE="STUDY">Chan 2005</LINK>).</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2010-02-18 14:24:52 +0000" MODIFIED_BY="[Empty name]">
<P>Two studies (<LINK REF="STD-Chan-2005" TYPE="STUDY">Chan 2005</LINK>; <LINK REF="STD-Fricke-2008" TYPE="STUDY">Fricke 2008</LINK>) scored 5/5, one (<LINK REF="STD-Zelenakas-2004" TYPE="STUDY">Zelenakas 2004</LINK>) scored 4/5 and one (<LINK REF="STD-Kellstein-2004" TYPE="STUDY">Kellstein 2004</LINK>) scored 3/5 on the Oxford Quality Score. Points were lost due to failure to adequately describe the methods of randomisation, and <LINK REF="STD-Kellstein-2004" TYPE="STUDY">Kellstein 2004</LINK> did not report on withdrawals. Details are in the "Characetistics of included studies" table.</P>
<P>The Risk of bias table did not indicate significant risk of bias in any study (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2010-03-05 14:30:29 +0000" MODIFIED_BY="[Empty name]">
<P>Four studies provided data for analysis. Three studies (<LINK REF="STD-Chan-2005" TYPE="STUDY">Chan 2005</LINK>; <LINK REF="STD-Fricke-2008" TYPE="STUDY">Fricke 2008</LINK>; <LINK REF="STD-Kellstein-2004" TYPE="STUDY">Kellstein 2004</LINK>) assessed one 400 mg single dose of lumiracoxib. The other (<LINK REF="STD-Zelenakas-2004" TYPE="STUDY">Zelenakas 2004</LINK>) assessed 400 and 100 mg doses. Data analysis was carried out on 366 patients who received lumiracoxib 400 mg, and the 212 patients who received placebo. No analysis was carried out for the 51 participants receiving lumiracoxib 100 mg in <LINK REF="STD-Zelenakas-2004" TYPE="STUDY">Zelenakas 2004</LINK>, as patient numbers were too small (<LINK REF="REF-Moore-1998" TYPE="REFERENCE">Moore 1998</LINK>).<B>
<BR/>
</B>
<BR/>Novartis Pharmaceuticals kindly supplied tables of pain relief over time for three trials (<LINK REF="STD-Chan-2005" TYPE="STUDY">Chan 2005</LINK>; <LINK REF="STD-Kellstein-2004" TYPE="STUDY">Kellstein 2004</LINK>; <LINK REF="STD-Zelenakas-2004" TYPE="STUDY">Zelenakas 2004</LINK>). Patient data was not available for one patient in each of the lumiracoxib 400 mg and placebo arms of the <LINK REF="STD-Chan-2005" TYPE="STUDY">Chan 2005</LINK> study, although these patients completed the study. For efficacy outcomes, these patients were assumed to have not had an event, and the study did not contribute data for adverse event analysis. No study authors supplied any additional information.</P>
<P>Details of efficacy outcomes, and adverse events and withdrawals in individual studies are available in <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK> and <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> respectively.</P>
<SUBSECTION>
<HEADING LEVEL="3">Efficacy</HEADING>
<P>Details of efficacy outcomes in individual studies are in <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>, and of adverse events and withdrawals in <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="4">Participants achieving at least 50% pain relief over 6 hours</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Lumiracoxib 400 mg versus placebo</HEADING>
<P>Four studies provided data (<LINK REF="STD-Chan-2005" TYPE="STUDY">Chan 2005</LINK>; <LINK REF="STD-Fricke-2008" TYPE="STUDY">Fricke 2008</LINK>; <LINK REF="STD-Kellstein-2004" TYPE="STUDY">Kellstein 2004</LINK>; <LINK REF="STD-Zelenakas-2004" TYPE="STUDY">Zelenakas 2004</LINK>); 336 participants were treated with lumiracoxib 400 mg and 212 with placebo (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
<UL>
<LI>The proportion of participants experiencing at least 50% pain relief over six hours with lumiracoxib 400 mg was 50% (183/366).</LI>
<LI>The proportion of participants experiencing at least 50% pain relief over six hours with placebo was 8% (17/212).</LI>
<LI>The relative benefit of treatment compared with placebo was 6.9 (4.1 to 11).</LI>
<LI>The NNT for at least 50% pain relief over six hours for lumiracoxib 400 mg compared with placebo was 2.4 (2.1 to 2.8). For every five participants treated with lumiracoxib 400 mg, two would experience at least 50% pain relief who would not have done so with placebo.</LI>
</UL>
<P>(<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>)</P>
<SUBSECTION>
<HEADING LEVEL="6">Subgroup analysis for pain model</HEADING>
<P>There were insufficient data from non-dental studies to compare the two groups, but removing the study in orthopaedic surgery from the analysis gave a relative benefit of 9.7 (4.3 to 22), and an NNT of 2.1 (1.8 to 2.7).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Sensitivity analyses</HEADING>
<P>All included studies had more than 40 participants in each treatment group, and all scored 3/5 or more on the Oxford Quality Score, so no sensitivity analyses could be carried out for these criteria.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Lumiracoxib versus active comparators</HEADING>
<P>There were insufficient data to allow direct comparison between lumiracoxib 400 mg and any individual active comparator.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Time to onset of analgesia</HEADING>
<P>The median time to onset of analgesia for lumiracoxib 400 mg was 1.5 hours in <LINK REF="STD-Chan-2005" TYPE="STUDY">Chan 2005</LINK>, 0.6 hours in <LINK REF="STD-Fricke-2008" TYPE="STUDY">Fricke 2008</LINK>, 0.7 hours in <LINK REF="STD-Kellstein-2004" TYPE="STUDY">Kellstein 2004</LINK>, and 0.6 hours in <LINK REF="STD-Zelenakas-2004" TYPE="STUDY">Zelenakas 2004</LINK>. In all studies the median time to onset for placebo was not estimable (&gt;12 hours), because the number of participants achieving onset was too low.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Use of rescue medication</HEADING>
<P>Two studies reported numbers of patients requiring rescue medication within 12 hours (<LINK REF="STD-Chan-2005" TYPE="STUDY">Chan 2005</LINK>; <LINK REF="STD-Zelenakas-2004" TYPE="STUDY">Zelenakas 2004</LINK>), and one within 24 hours (<LINK REF="STD-Fricke-2008" TYPE="STUDY">Fricke 2008</LINK>). These were combined for analysis as it was likely that most participants requiring rescue medication following dental surgery would have done so by 12 hours, and the data for Fricke were very similar to the others (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
<UL>
<LI>The proportion of participants requiring rescue medication within 12 to 24 hours with lumiracoxib 400 mg was 64% (169/266).</LI>
<LI>The proportion of participants requiring rescue medication within 12 to 24 hours with placebo was 91% (147/162).</LI>
<LI>The relative risk of treatment compared with placebo was 0.68 (0.61 to 0.76).</LI>
<LI>The NNT to prevent use of rescue medication within 12 to 24 hours for lumiracoxib 400 mg compared with placebo was 3.7 (2.9 to 5.0). For every four participants treated with lumiracoxib 400 mg, one would not require rescue medication within 12 to 24 hours who would have done with placebo.</LI>
</UL>
<P>Median time to use of rescue medication was reported for all trials, ranging from 3.8 hours to &gt;12 hours for lumiracoxib 400 mg, and 1.3 to 2 hours for placebo. The weighted mean of the median time to use of rescue medication was 9.4 hours for lumiracoxib 400 mg and 1.7 for placebo. The short time of 3.8 hours reported in Chan 2005 may reflect that this study was carried out in orthopaedic patients, while the others were in dental patients. For dental studies only the median time to use of rescue medication was 10.5 hours with lumiracoxib 400 mg.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Patient global assessment</HEADING>
<P>All studies used a four point scale (poor, fair, good and excellent). The numbers of patients reporting 'excellent' at 12 hours were 116/366 (32%) for lumiracoxib and 6/213 (3%) for placebo.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse events and withdrawals</HEADING>
<P>One study (<LINK REF="STD-Chan-2005" TYPE="STUDY">Chan 2005</LINK>) appeared to report adverse events only at 96 hours, after a multiple dose phase, so provided no data for this analysis. Details of methods used to collect adverse events (spontaneous report, open question list) were not consistently reported.</P>
<P>Three studies (<LINK REF="STD-Fricke-2008" TYPE="STUDY">Fricke 2008</LINK>; <LINK REF="STD-Kellstein-2004" TYPE="STUDY">Kellstein 2004</LINK>; <LINK REF="STD-Zelenakas-2004" TYPE="STUDY">Zelenakas 2004</LINK>, 252 participants) provided information on numbers of patients with one or more adverse events (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
<UL>
<LI>The proportion of participants experiencing at least one adverse event with lumiracoxib 400 mg was 15% (22/151);</LI>
<LI>The proportion of participants experiencing at least one adverse event with placebo was 19% (19/101);</LI>
<LI>The relative benefit of treatment compared with placebo was 0.69 (0.37 to 1.27);</LI>
<LI>The NNT was not calculated.</LI>
</UL>
<P>There was only one withdrawal due to an adverse event, in a patient given ibuprofen, who had postoperative bleeding at the suture site (<LINK REF="STD-Zelenakas-2004" TYPE="STUDY">Zelenakas 2004</LINK>). There was no reported adjudication of relationship to the test drug. There was also only one serious adverse event, in a patient given placebo, who had a deep vein thrombosis (DVT) (<LINK REF="STD-Zelenakas-2004" TYPE="STUDY">Zelenakas 2004</LINK>).</P>
<P>Adverse events were generally described as mild to moderate in severity, and were probably mostly related to the postoperative status of the patients.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2010-06-15 14:03:18 +0100" MODIFIED_BY="Caroline Struthers">
<SUMMARY_OF_RESULTS MODIFIED="2010-03-05 13:53:10 +0000" MODIFIED_BY="[Empty name]">
<P>This review is an update of an earlier Cochrane review published in 2007, and examines the efficacy of lumiracoxib, a COX-2 inhibitor, in providing postoperative pain relief. Four studies fulfilled inclusion criteria, three following dental surgery (<LINK REF="STD-Fricke-2008" TYPE="STUDY">Fricke 2008</LINK>; <LINK REF="STD-Kellstein-2004" TYPE="STUDY">Kellstein 2004</LINK>; <LINK REF="STD-Zelenakas-2004" TYPE="STUDY">Zelenakas 2004</LINK>), and one (<LINK REF="STD-Chan-2005" TYPE="STUDY">Chan 2005</LINK>) following orthopaedic surgery. The addition of <LINK REF="STD-Fricke-2008" TYPE="STUDY">Fricke 2008</LINK> in this update increases the number of participants treated with lumiracoxib 400 mg by 73%, giving greater confidence in results, although the overall findings are not changed. There remain no, or insufficient, data for analysis of doses other than 400 mg.</P>
<P>With lumiracoxib 400 mg, half of participants experienced at least 50% pain relief over 6 hours, compared to less than 10% with placebo; the NNT was 2.4 (2.1 to 2.8). Fewer participants needed rescue medication at any point during the study (12 or 24 hours) with lumiracoxib (64%) than with placebo (91%), and the median time to use of rescue medication was 9.4 hours for lumiracoxib and 1.7 hours for placebo. Results of the four studies were in good agreement (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>), and while results from the study in orthopaedic surgery (<LINK REF="STD-Chan-2005" TYPE="STUDY">Chan 2005</LINK>) might be taken to suggest that lumiracoxib is less effective in this situation, such a conclusion cannot be drawn with only 118 participants.</P>
<P>Adverse events did not occur more often with lumiracoxib than placebo, and there were no serious adverse events or withdrawals due to adverse events in participants treated with lumiracoxib in these studies.</P>
<P>Indirect comparisons of NNTs for at least 50% pain relief over 4 to 6 hours in reviews of other analgesics using identical methods indicate that lumiracoxib has equivalent efficacy to ibuprofen 400 mg (<LINK REF="REF-Derry-C-2009b" TYPE="REFERENCE">Derry C 2009b</LINK>; NNT 2.5 (2.4 to 2.6)), is more effective than paracetamol 1000 mg (<LINK REF="REF-Toms-2008" TYPE="REFERENCE">Toms 2008</LINK>; NNT 3.6 (3.4 to 4.0)) and less effective than etoricoxib 120 mg (<LINK REF="REF-Clarke-2009" TYPE="REFERENCE">Clarke 2009</LINK>; 1.9 (1.7 to 2.1)).</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2010-06-15 14:03:18 +0100" MODIFIED_BY="Caroline Struthers">
<P>Most of the data came from participants who had third molar dental extractions, who are generally in their early twenties, and otherwise fit and healthy; other patient groups may not give an identical response. There were insufficient data to determine whether type of surgery influenced outcome. A review in 2004 found no systematic difference in analgesic response between dental and other types of surgery (<LINK REF="REF-Barden-2004" TYPE="REFERENCE">Barden 2004</LINK>), but this will be addressed in a planned Cochrane overview of analgesics in acute postoperative pain.</P>
<P>Information on adverse events was not reported by all studies, and single dose studies are not designed to investigate drug safety, so the results presented in this review should be interpreted within the context of these studies.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2010-03-04 14:54:57 +0000" MODIFIED_BY="[Empty name]">
<P>The methodological quality of the included studies was good, with all scoring adequately on the Oxford Quality Score and Cochrane Risk of Bias assessment to avoid risk of bias from randomisation, blinding and withdrawals. All the studies in the review used "last observation carried forward" (LOCF) for missing data, for example when a patient uses rescue medication and provides no further efficacy measurements. This tends to overestimate efficacy compared with placebo, and the degree of overestimation increases with time as more patients use rescue medication, so that analyses over periods greater than six hours become unreliable (<LINK REF="REF-Moore-2005a" TYPE="REFERENCE">Moore 2005a</LINK>). We chose to analyse pain relief at 6 hours to avoid problems with LOCF, and for comparability with many other reviews.</P>
<P>All studies enrolled participants with established pain following surgery, with pain levels sufficient to demonstrate reduction, or otherwise, due to treatment.</P>
<P>All studies were funded by the manufacturer of lumiracoxib. Such involvement does not necessarily imply bias, as long as original data rather than authors' conclusions are utilised, and study validity is not compromised (<LINK REF="REF-Barden-2006" TYPE="REFERENCE">Barden 2006</LINK>); these criteria have been satisfied here.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2010-03-05 13:57:20 +0000" MODIFIED_BY="[Empty name]">
<P>The included studies were identified from a comprehensive search of published papers, and standard methods have been used for analysis. We cannot exclude the possibility that undiscovered studies exist that show no benefit, but we can calculate the number of participants in trials of zero benefit (relative risk of 1) that would be required for the absolute benefit to reduce beneficial effects to a negligible amount (<LINK REF="REF-Moore-2008" TYPE="REFERENCE">Moore 2008</LINK>). If an NNT of 8 for at least 50% pain relief were considered clinically irrelevant, then there would have to be 1349 participants in zero effect studies. This would require at least 13 studies with 100 participants, and that number of unavailable studies seems unlikely.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2010-03-05 13:57:34 +0000" MODIFIED_BY="[Empty name]">
<P>We know of no other reviews of lumiracoxib in acute postoperative pain.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2010-02-18 13:23:40 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2010-02-18 13:23:04 +0000" MODIFIED_BY="[Empty name]">
<P>This review has found that lumiracoxib is effective at providing postoperative pain relief in approximately half of adult patients, and is comparable to ibuprofen 400 mg, but with a median time to use of rescue medication it has a longer duration of analgesia.  It was not associated with any serious adverse events in this limited data set.<B>
<BR/>
</B>
</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2010-02-18 13:23:40 +0000" MODIFIED_BY="[Empty name]">
<P>We see no implications for research in the field of single dose acute pain studies. What is lacking are pragmatic studies determining how to ensure that patients achieve clinically relevant, say 50% pain relief, rather than exploratory studies which show that a drug is an analgesic.</P>
<P>In terms of adverse event profiles, this is difficult in a drug like lumiracoxib when it is used for short term studies only. A possible approach might be to study time to event data in large trials of chronic use, although the study population is likely to differ.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2010-02-18 13:24:18 +0000" MODIFIED_BY="[Empty name]">
<P>Novartis Pharmaceuticals were contacted for the initial review and kindly supplied information on two new ongoing trials. They also supplied additional data for the included studies.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2010-06-15 14:09:00 +0100" MODIFIED_BY="Caroline Struthers">
<P>SD and RAM have received research support from charities, government and industry sources at various times, but no such support was received for this work. RAM and HJM have consulted for various pharmaceutical companies. RAM has received lecture fees from pharmaceutical companies related to analgesics and other healthcare interventions. YMR is employed by the PaPaS Review Group.<BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2010-06-15 14:13:39 +0100" MODIFIED_BY="Caroline Struthers">
<P>For the earlier review YMR helped complete the search strategy, accessed papers, and obtained additional data for the review, and SD and YMR carried out data extraction and analysis and wrote the review. RAM conceived the idea for the review and helped with editorial and statistical analyses.</P>
<P>For the update SD carried out searches, data extraction and analysis. All authors were involved with writing the update.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES MODIFIED="2017-07-24 12:26:59 +0100" MODIFIED_BY="Anna Erskine">
<P>A restricted search in July 2017 did not identify any potentially relevant studies. We are confident that more research in this area is unlikely. Therefore, this review has now been stabilised following discussion with the authors and editors, and is available for historical interest only.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2017-07-24 12:27:31 +0100" MODIFIED_BY="Anna Erskine">
<STUDIES MODIFIED="2010-03-05 11:40:36 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2010-02-18 09:50:15 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Chan-2005" NAME="Chan 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chan VWS, Clark A J, Davis JC, Wolf RS, Kellstein D, Jayawardene S</AU>
<TI>The post-operative analgesic efficacy and tolerability of lumiracoxib compared with placebo and naproxen after total knee or hip arthroplasty</TI>
<SO>Acta Anaesthesiologica Scandinavica</SO>
<YR>2005</YR>
<VL>Nov 49</VL>
<NO>10</NO>
<PG>1491-500</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2881624"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2881623"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fricke-2008" MODIFIED="2010-02-18 09:50:15 +0000" MODIFIED_BY="[Empty name]" NAME="Fricke 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-02-18 09:50:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fricke J, Davis N, Yu V, Krammer G</AU>
<TI>Lumiracoxib 400 mg compared with celecoxib 400 mg and placebo for treating pain following dental surgery: a randomized, controlled trial</TI>
<SO>Journal of Pain</SO>
<YR>2008</YR>
<VL>9</VL>
<NO>1</NO>
<PG>20-7</PG>
<IDENTIFIERS MODIFIED="2010-02-18 09:50:15 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2881626"/><IDENTIFIER MODIFIED="2010-02-18 09:50:15 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/j.jpain.2007.08.004"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2881625"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kellstein-2004" NAME="Kellstein 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kellstein D, Ott D, Jayawardene S, Fricke J</AU>
<TI>Analgesic efficacy of a single dose of lumiracoxib compared with rofecoxib, celecoxib and placebo in the treatment of post-operative dental pain</TI>
<SO>International Journal of Clinical Practice</SO>
<YR>2004</YR>
<VL>58</VL>
<NO>3</NO>
<PG>244-50</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2881628"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2881627"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zelenakas-2004" NAME="Zelenakas 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zelenakas K, Fricke JR Jr, Jayawardene S, Kellstein D</AU>
<TI>Analgesic efficacy of single oral doses of lumiracoxib and ibuprofen in patients with postoperative dental pain</TI>
<SO>International Journal of Clinical Practice</SO>
<YR>2004</YR>
<VL>58</VL>
<NO>3</NO>
<PG>251-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2881630"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2881629"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Bitner-2004" NAME="Bitner 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bitner M, Katterhorn J, Hatfield C, Gao J, Kellstein D</AU>
<TI>Efficacy and tolerability of lumiracoxib in the treatment of primary dysmenorrhoea</TI>
<SO>International Journal Clinical Practice</SO>
<YR>2004</YR>
<VL>58</VL>
<NO>4</NO>
<PG>340-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2881632"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2881631"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schnitzer-2004" NAME="Schnitzer 2004" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schnitzer TJ, Beier J, Geusens P, Hasler P, Patel SK, Senftleber I, et al</AU>
<TI>Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: A phase II, four week, multicenter randomised, double blind, placebo-controlled trial</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2004</YR>
<VL>51</VL>
<NO>4</NO>
<PG>549-57</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2881634"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2881633"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2010-03-05 11:40:36 +0000" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2010-03-05 14:04:57 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2010-03-05 14:04:57 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Bannwarth-2005" NAME="Bannwarth 2005" TYPE="JOURNAL_ARTICLE">
<AU>Bannworth B, Berenbaum F</AU>
<TI>Clinical pharmacology of lumiracoxib, a second generation cyclooxygenase 2 selective inhibitor</TI>
<SO>Expert Opinion on Investigational Drugs</SO>
<YR>2005</YR>
<VL>14</VL>
<NO>4</NO>
<PG>521-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barden-2004" NAME="Barden 2004" TYPE="JOURNAL_ARTICLE">
<AU>Barden J, Edwards JE, McQuay HJ, Moore RA</AU>
<TI>Pain and analgesic response after third molar extraction and other postsurgical pain</TI>
<SO>Pain</SO>
<YR>2004</YR>
<VL>107</VL>
<PG>86-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barden-2006" MODIFIED="2010-02-18 16:30:45 +0000" MODIFIED_BY="[Empty name]" NAME="Barden 2006" TYPE="JOURNAL_ARTICLE">
<AU>Barden J, Derry S, McQuay HJ, Moore RA</AU>
<TI>Bias from industry trial funding? A framework, a suggested approach, and a negative result</TI>
<SO>Pain</SO>
<YR>2006</YR>
<VL>121</VL>
<NO>3</NO>
<PG>207-18</PG>
<IDENTIFIERS MODIFIED="2010-02-18 16:30:30 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-02-18 16:30:30 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/j.pain.2005.12.011"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Clarke-2009" MODIFIED="2010-02-18 16:34:24 +0000" MODIFIED_BY="[Empty name]" NAME="Clarke 2009" TYPE="COCHRANE_REVIEW">
<AU>Clarke R, Derry S, Moore RA, McQuay HJ</AU>
<TI>Single dose oral etoricoxib for postoperative pain</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2010-02-18 16:33:53 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-02-18 16:33:53 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004309.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Collins-2001" MODIFIED="2010-02-18 16:36:51 +0000" MODIFIED_BY="[Empty name]" NAME="Collins 2001" TYPE="JOURNAL_ARTICLE">
<AU>Collins SL, Edwards J, Moore RA, Smith LA, McQuay HJ</AU>
<TI>Seeking a simple measure of analgesia for mega-trials: is a single global assessment good enough?</TI>
<SO>Pain</SO>
<YR>2001</YR>
<VL>91</VL>
<NO>(1-2)</NO>
<PG>189-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cook-1995" NAME="Cook 1995" TYPE="JOURNAL_ARTICLE">
<AU>Cook RJ, Sackett DL</AU>
<TI>The number needed to treat: a clinically useful measure of treatment effect</TI>
<SO>BMJ</SO>
<YR>1995</YR>
<VL>310</VL>
<PG>452-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cooper-1991" NAME="Cooper 1991" TYPE="BOOK_SECTION">
<AU>Cooper SA</AU>
<TI>Single-dose analgesic studies: the upside and downside of assay sensitivity</TI>
<SO>The design of analgesic clinical trials. Advances in Pain Research and Therapy</SO>
<YR>1991</YR>
<VL>18</VL>
<PG>117-24</PG>
<ED>Max MB, Portenoy RK, Laska EM</ED>
<PB>Raven Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Day-1988" NAME="Day 1988" TYPE="JOURNAL_ARTICLE">
<AU>Day RO, McLachlan AJ, Graham GG, Williams KM</AU>
<TI>Pharmokinetics of non-steroidal anti-inflammatory drugs in synovial fluid</TI>
<SO>Baillieres Clinical Rheumatology</SO>
<YR>1988</YR>
<VL>2</VL>
<PG>363-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Derry-2008" MODIFIED="2010-02-18 17:45:11 +0000" MODIFIED_BY="[Empty name]" NAME="Derry 2008" TYPE="COCHRANE_REVIEW">
<AU>Derry S, Barden J, McQuay HJ, Moore RA</AU>
<TI>Single dose oral celecoxib for acute postoperative pain in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2010-02-18 17:45:11 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-02-18 17:45:11 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004233.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Derry-C-2009a" MODIFIED="2010-02-18 17:37:49 +0000" MODIFIED_BY="[Empty name]" NAME="Derry C 2009a" TYPE="COCHRANE_REVIEW">
<AU>Derry C, Derry S, Moore RA, McQuay HJ</AU>
<TI>Single dose oral naproxen and naproxen sodium for acute postoperative pain in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2010-02-18 17:37:49 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-02-18 17:37:49 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004234.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Derry-C-2009b" MODIFIED="2010-02-18 17:42:27 +0000" MODIFIED_BY="[Empty name]" NAME="Derry C 2009b" TYPE="COCHRANE_REVIEW">
<AU>Derry C, Derry S, Moore RA, McQuay HJ</AU>
<TI>Single dose oral ibuprofen for acute postoperative pain in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2010-02-18 17:42:27 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-02-18 17:42:27 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001548"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Derry-P-2009" MODIFIED="2010-02-18 17:39:31 +0000" MODIFIED_BY="[Empty name]" NAME="Derry P 2009" TYPE="COCHRANE_REVIEW">
<AU>Derry P, Derry S, Moore RA, McQuay HJ</AU>
<TI>Single dose oral diclofenac for acute postoperative pain in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2010-02-18 17:39:31 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-02-18 17:39:31 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004768.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fitzgerald-2001" MODIFIED="2010-02-18 16:42:25 +0000" MODIFIED_BY="[Empty name]" NAME="Fitzgerald 2001" TYPE="JOURNAL_ARTICLE">
<AU>FitzGerald GA, Patrono C</AU>
<TI>The coxibs, selective inhibitors of cyclooxygenase-2</TI>
<SO>New England Journal of Medicine</SO>
<YR>2001</YR>
<VL>345</VL>
<NO>6</NO>
<PG>433-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Forrest-2002" MODIFIED="2010-02-18 16:55:42 +0000" MODIFIED_BY="[Empty name]" NAME="Forrest 2002" TYPE="JOURNAL_ARTICLE">
<AU>Forrest JB, Camu F, Greer IA, Kehlet H, Abdalla M, Bonnet F</AU>
<TI>Ketorolac, diclofenac, and ketoprofen are equally safe for pain relief after major surgery</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>2002</YR>
<VL>88</VL>
<NO>2</NO>
<PG>227-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Garner-2002" MODIFIED="2010-02-18 17:51:22 +0000" MODIFIED_BY="[Empty name]" NAME="Garner 2002" TYPE="COCHRANE_REVIEW">
<AU>Garner S, Fidan D, Frankish R, Judd M, Towheed T, Wells G, Tugwell P</AU>
<TI>Rofecoxib for the treatment of rheumatoid arthritis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2010-02-18 17:51:22 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-02-18 17:51:22 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003685.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Grahame_x002d_Smith-2002" MODIFIED="2010-02-18 16:57:01 +0000" MODIFIED_BY="[Empty name]" NAME="Grahame-Smith 2002" TYPE="BOOK">
<AU>Grahame-Smith DG, Aronson JK</AU>
<SO>Oxford textbook of clinical pharmacology and drug therapy</SO>
<YR>2002</YR>
<EN>3rd</EN>
<PB>Oxford University Press</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hawkey-1999" MODIFIED="2010-02-18 16:43:42 +0000" MODIFIED_BY="[Empty name]" NAME="Hawkey 1999" TYPE="JOURNAL_ARTICLE">
<AU>Hawkey CJ</AU>
<TI>Cox-2 inhibitors</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>353</VL>
<NO>9149</NO>
<PG>307-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hawkey-2001" MODIFIED="2010-02-18 17:01:14 +0000" MODIFIED_BY="[Empty name]" NAME="Hawkey 2001" TYPE="JOURNAL_ARTICLE">
<AU>Hawkey CJ</AU>
<TI>Gastrointestinal safety of COX-2 specific inhibitors</TI>
<SO>Gastroenterology Clinics of North America</SO>
<YR>2001</YR>
<VL>30</VL>
<NO>4</NO>
<PG>921-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hawkey-2006" MODIFIED="2010-02-18 17:02:49 +0000" MODIFIED_BY="[Empty name]" NAME="Hawkey 2006" TYPE="JOURNAL_ARTICLE">
<AU>Hawkey CJ</AU>
<TI>NSAIDs, coxibs, and the intestine</TI>
<SO>Journal of Cardiovascular Pharmacology</SO>
<YR>2006</YR>
<VL>47(Suppl 1)</VL>
<PG>S72-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" MODIFIED="2010-02-18 17:33:33 +0000" MODIFIED_BY="[Empty name]" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al</AU>
<TI>Assessing the quality of reports of randomized clinical trials: is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kearney-2006" NAME="Kearney 2006" TYPE="JOURNAL_ARTICLE">
<AU>Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono</AU>
<TI>Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials</TI>
<SO>BMJ</SO>
<YR>2006</YR>
<VL>332</VL>
<PG>1302-08</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-L_x0027_Abbe-1987" MODIFIED="2010-02-18 16:44:53 +0000" MODIFIED_BY="[Empty name]" NAME="L'Abbe 1987" TYPE="JOURNAL_ARTICLE">
<AU>L'Abbe KA, Detsky AS, O'Rourke K</AU>
<TI>Meta-analysis in clinical research</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1987</YR>
<VL>107</VL>
<PG>224-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lloyd-2009" MODIFIED="2010-02-18 17:41:41 +0000" MODIFIED_BY="[Empty name]" NAME="Lloyd 2009" TYPE="COCHRANE_REVIEW">
<AU>Lloyd R, Derry S, Moore RA, McQuay HJ</AU>
<TI>Intravenous parecoxib for acute postoperative pain in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2010-02-18 17:41:41 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-02-18 17:41:41 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004771.pub4"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-McQuay-2005" MODIFIED="2010-02-18 16:46:36 +0000" MODIFIED_BY="[Empty name]" NAME="McQuay 2005" TYPE="JOURNAL_ARTICLE">
<AU>McQuay HJ, Moore RA</AU>
<TI>Placebo</TI>
<SO>Postgraduate Medical Journal</SO>
<YR>2005</YR>
<VL>81</VL>
<PG>155-60</PG>
<IDENTIFIERS MODIFIED="2010-02-18 16:46:26 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-02-18 16:46:26 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1136/pgmj.2004.024737"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moher-1999" MODIFIED="2010-02-18 17:47:19 +0000" MODIFIED_BY="[Empty name]" NAME="Moher 1999" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF</AU>
<TI>Improving the quality of meta-analyses of randomised controlled trials: the QUOROM statement</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>354</VL>
<PG>1896-900</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moore-1996" NAME="Moore 1996" TYPE="JOURNAL_ARTICLE">
<AU>Moore A, McQuay H, Gavaghan D</AU>
<TI>Deriving dichotomous outcome measures from continuous data in randomised controlled trials of analgesics</TI>
<SO>Pain</SO>
<YR>1996</YR>
<VL>66</VL>
<NO>2-3</NO>
<PG>229-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moore-1997a" NAME="Moore 1997a" TYPE="JOURNAL_ARTICLE">
<AU>Moore A, McQuay H, Gavaghan D</AU>
<TI>Deriving dichotomous outcome measures from continuous data in randomised controlled trials of analgesics: Verification from independent data</TI>
<SO>Pain</SO>
<YR>1997</YR>
<VL>69</VL>
<NO>1-2</NO>
<PG>127-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moore-1997b" NAME="Moore 1997b" TYPE="JOURNAL_ARTICLE">
<AU>Moore A, Moore O, McQuay H, Gavaghan D</AU>
<TI>Deriving dichotomous outcome measures from continuous data in randomised controlled trials of analgesics: Use of pain intensity and visual analogue scales</TI>
<SO>Pain</SO>
<YR>1997</YR>
<VL>69</VL>
<NO>3</NO>
<PG>311-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moore-1998" NAME="Moore 1998" TYPE="JOURNAL_ARTICLE">
<AU>Moore RA, Gavaghan D, Tramer MR, Collins SL, McQuay HJ</AU>
<TI>Size is everything - large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects</TI>
<SO>Pain</SO>
<YR>1998</YR>
<VL>78</VL>
<NO>3</NO>
<PG>209-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moore-2003" MODIFIED="2010-02-18 16:50:39 +0000" MODIFIED_BY="[Empty name]" NAME="Moore 2003" TYPE="BOOK">
<AU>Moore RA, Edwards J, Barden J, McQuay HJ</AU>
<SO>Bandolier's Little Book of Pain</SO>
<YR>2003</YR>
<PB>Oxford University Press</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2010-02-18 16:50:22 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-02-18 16:50:22 +0000" MODIFIED_BY="[Empty name]" OTHERTYPE="ISBN" TYPE="OTHER" VALUE="0-19-263247-7"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moore-2005a" MODIFIED="2010-02-18 17:29:22 +0000" MODIFIED_BY="[Empty name]" NAME="Moore 2005a" TYPE="JOURNAL_ARTICLE">
<AU>Moore RA, Edwards JE, McQuay HJM</AU>
<TI>Acute pain: individual patient meta-analysis shows the impact of different ways of analysing and presenting results</TI>
<SO>Pain</SO>
<YR>2005</YR>
<VL>116</VL>
<PG>322-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moore-2005b" MODIFIED="2010-02-18 17:04:59 +0000" MODIFIED_BY="[Empty name]" NAME="Moore 2005b" TYPE="JOURNAL_ARTICLE">
<AU>Moore RA, Derry S, Makinson GT, McQuay HJ</AU>
<TI>Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports</TI>
<SO>Arthritis Research and Therapeutics</SO>
<YR>2005</YR>
<VL>7</VL>
<NO>3</NO>
<PG>R644-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moore-2006" MODIFIED="2010-02-18 16:48:48 +0000" MODIFIED_BY="[Empty name]" NAME="Moore 2006" TYPE="BOOK">
<AU>Moore A, McQuay H</AU>
<SO>Bandolier's Little Book of Making Sense of the Medical Evidence</SO>
<YR>2006</YR>
<PB>Oxford University Press</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2010-02-18 16:48:36 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-02-18 16:48:36 +0000" MODIFIED_BY="[Empty name]" OTHERTYPE="ISBN" TYPE="OTHER" VALUE="0-19-856604-2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moore-2008" MODIFIED="2010-03-05 13:56:58 +0000" MODIFIED_BY="[Empty name]" NAME="Moore 2008" TYPE="BOOK_SECTION">
<AU>Moore RA, Barden J, Derry S, McQuay HJ</AU>
<TI>Managing potential publication bias</TI>
<SO>Systematic Reviews in Pain Research: Methodology Refined</SO>
<YR>2008</YR>
<PG>15-24</PG>
<ED>McQuay HJ, Kalso E, Moore RA</ED>
<PB>IASP Press</PB>
<CY>Seattle</CY>
<IDENTIFIERS MODIFIED="2010-03-05 13:56:58 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-03-05 13:56:58 +0000" MODIFIED_BY="[Empty name]" OTHERTYPE="ISBN" TYPE="OTHER" VALUE="978-0-931092-69-5"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Morris-1995" NAME="Morris 1995" TYPE="BOOK_SECTION">
<AU>Morris JA, Gardner MJ</AU>
<TI>Calculating confidence intervals for relative risk, odds ratio and standardised ratios and rates</TI>
<SO>Statistics with confidence - confidence intervals and statistical guidelines</SO>
<YR>1995</YR>
<PG>50-63</PG>
<ED>Gardner MJ, Altman DG</ED>
<PB>BMJ</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mysler-2004" NAME="Mysler 2004" TYPE="JOURNAL_ARTICLE">
<AU>Mysler E</AU>
<TI>Lumiracoxib (Prexige): a new selective COX-2 inhibitor</TI>
<SO>International Journal of Clinical Practice</SO>
<YR>2004</YR>
<VL>58</VL>
<NO>6</NO>
<PG>606-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Patrono-2009" MODIFIED="2010-03-04 16:10:27 +0000" MODIFIED_BY="[Empty name]" NAME="Patrono 2009" TYPE="JOURNAL_ARTICLE">
<AU>Patrono C, Baigent C</AU>
<TI>Low-dose aspirin, coxibs, and other NSAIDS: a clinical mosaic emerges</TI>
<SO>Molecular Interventions</SO>
<YR>2009</YR>
<VL>9</VL>
<NO>1</NO>
<PG>31-9</PG>
<IDENTIFIERS MODIFIED="2010-03-04 16:10:27 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-03-04 16:10:27 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1124/mi.9.1.8"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Schnitzer-2004a" NAME="Schnitzer 2004a" TYPE="JOURNAL_ARTICLE">
<AU>Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, et al</AU>
<TI>Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>2004</YR>
<VL>364</VL>
<NO>9435</NO>
<PG>665-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Toms-2008" MODIFIED="2010-02-18 16:52:54 +0000" MODIFIED_BY="[Empty name]" NAME="Toms 2008" TYPE="COCHRANE_REVIEW">
<AU>Toms L, McQuay HJ, Derry S, Moore RA</AU>
<TI>Single dose oral paracetamol (acetaminophen) for postoperative pain in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2010-02-18 16:52:43 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-02-18 16:52:43 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004602"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Toms-2009" MODIFIED="2010-02-18 17:08:03 +0000" MODIFIED_BY="[Empty name]" NAME="Toms 2009" TYPE="COCHRANE_REVIEW">
<AU>Toms L, Derry S, Moore RA, McQuay HJ</AU>
<TI>Single dose oral paracetamol (acetaminophen) with codeine for postoperative pain in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2010-02-18 17:08:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-02-18 17:08:03 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001547.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tramer-1997" MODIFIED="2010-02-18 16:58:45 +0000" MODIFIED_BY="[Empty name]" NAME="Tramer 1997" TYPE="JOURNAL_ARTICLE">
<AU>Tramèr MR, Reynolds DJM, Moore RA, McQuay HJ</AU>
<TI>Impact of covert duplicate results on meta-analysis: a case study</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>635-9</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2010-02-18 17:32:06 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Roy-2007" MODIFIED="2010-02-18 17:32:06 +0000" MODIFIED_BY="[Empty name]" NAME="Roy 2007" TYPE="COCHRANE_REVIEW">
<AU>Roy YM, Derry S, Moore RA</AU>
<TI>Single dose oral lumiracoxib for postoperative pain</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2010-02-18 17:32:06 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-02-18 17:32:06 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006865"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2010-03-05 11:40:36 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2010-03-05 11:39:22 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2010-02-18 13:46:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chan-2005">
<CHAR_METHODS MODIFIED="2010-02-18 13:40:04 +0000" MODIFIED_BY="[Empty name]">
<P>RCT, DB, DD, placebo and active controlled parallel-group study, 12 hour single dose phase, followed by multi-dose phase up to 96 hours. Medication administered when pain intensity was moderate to severe</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-18 13:45:16 +0000" MODIFIED_BY="[Empty name]">
<P>Post operative total knee or hip arthroplasty surgery</P>
<P>Male and females<BR/>Mean age 64 years (SD 11.0, range 18 to 80 years)</P>
<P>N = 180</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-18 13:46:32 +0000" MODIFIED_BY="[Empty name]">
<P>Lumiracoxib 400 mg, n = 60</P>
<P>Naproxen 500 mg, n = 60</P>
<P>Placebo, n = 60</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-18 13:33:09 +0000" MODIFIED_BY="[Empty name]">
<P>&#8805;50% PR over six hours</P>
<P>Time to onset of analgesia</P>
<P>Use of rescue medication</P>
<P>Adverse events</P>
<P>Withdrawals</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-02-18 13:33:40 +0000" MODIFIED_BY="[Empty name]">
<P>Oxford Quality Score: R2, DB2, W1. Total = 5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-18 13:46:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fricke-2008">
<CHAR_METHODS MODIFIED="2010-02-18 13:43:22 +0000" MODIFIED_BY="[Empty name]">
<P>RCT, DB, DD, placebo and active controlled parallel group study, single oral dose. Medication administered when pain intensity was moderate to severe. Study duration 24 hours</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-18 13:45:33 +0000" MODIFIED_BY="[Empty name]">
<P>Post-operative dental surgery, third molar extraction</P>
<P>Male and females<BR/>Mean age 23 years (range 18 to 52 years)</P>
<P>N = 364</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-18 13:46:15 +0000" MODIFIED_BY="[Empty name]">
<P>Lumiracoxib 400 mg, n = 156</P>
<P>Celecoxib 400 mg, n = 156</P>
<P>Placebo, n = 52</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-18 13:46:46 +0000" MODIFIED_BY="[Empty name]">
<P>&#8805;50% PR over six hours</P>
<P>Time to onset of analgesia</P>
<P>Use of rescue medication</P>
<P>Adverse events</P>
<P>Withdrawals</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-02-18 13:46:54 +0000" MODIFIED_BY="[Empty name]">
<P>Oxford Quality Score: R2, DB2, W1. Total = 5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-18 13:54:00 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kellstein-2004">
<CHAR_METHODS MODIFIED="2010-02-18 13:41:04 +0000" MODIFIED_BY="[Empty name]">
<P>RCT, DB, DD, placebo and active controlled parallel group study, single oral dose. Medication administered when pain intensity was moderate to severe. Study duration 24 hours</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-18 13:53:52 +0000" MODIFIED_BY="[Empty name]">
<P>Post-operative dental surgery, third molar extraction</P>
<P>Male and females<BR/>Mean age 22 years (range 17 to 41 years)</P>
<P>N = 355</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-18 13:35:03 +0000" MODIFIED_BY="[Empty name]">
<P>Lumiracoxib 400 mg, n = 101</P>
<P>Rofecoxib 50 mg, n = 102</P>
<P>Celecoxib 200 mg, n = 101</P>
<P>Placebo, n = 51</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-18 13:36:05 +0000" MODIFIED_BY="[Empty name]">
<P>&#8805;50% PR over six hours</P>
<P>Time to onset of analgesia</P>
<P>Use of rescue medication</P>
<P>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-02-18 13:54:00 +0000" MODIFIED_BY="[Empty name]">
<P>Oxford Quality Score: R1, DB2, W0. Total = 3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-18 13:56:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zelenakas-2004">
<CHAR_METHODS MODIFIED="2010-02-18 13:41:45 +0000" MODIFIED_BY="[Empty name]">
<P>RCT, DB, DD, placebo and active controlled, parallel-group, single oral dose. Medication administered when pain intensity was moderate to severe. Study duration 12 hours</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-18 13:54:30 +0000" MODIFIED_BY="[Empty name]">
<P>Post-operative dental surgery, third molar extraction</P>
<P>Male and females<BR/>Mean age 22 years (SD 5.0, all &gt;17 years)</P>
<P>N = 202</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-18 13:54:55 +0000" MODIFIED_BY="[Empty name]">
<P>Lumiracoxib 400 mg, n = 50</P>
<P>Lumiracoxib 100 mg, n = 51</P>
<P>Ibuprofen 400 mg, n = 51</P>
<P>Placebo, n = 50</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-18 13:56:27 +0000" MODIFIED_BY="[Empty name]">
<P>&#8805;50% PR over six hours</P>
<P>Time to onset of analgesia</P>
<P>Use of rescue medication</P>
<P>Adverse events</P>
<P>Withdrawals</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-02-18 13:56:33 +0000" MODIFIED_BY="[Empty name]">
<P>Oxford Quality Score: R1, DB2, W1. Total = 4</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>DB - double blind, DD - Double Dummy, N - number of participants in study, n - number of participants in treatment arm, PR - pain relief, R - randomised, RCT - Randomised Controlled Trial, W - withdrawals<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Bitner-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not post operative pain</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schnitzer-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not post operative pain</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2010-03-05 11:40:36 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2010-03-04 14:44:40 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2010-03-04 14:44:40 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-04 14:44:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chan-2005">
<DESCRIPTION>
<P>"validated automated system" </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-18 14:06:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fricke-2008">
<DESCRIPTION>
<P>"validated automated system" </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-18 13:36:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kellstein-2004">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-18 13:37:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zelenakas-2004">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2010-02-18 14:06:26 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-18 14:06:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chan-2005">
<DESCRIPTION>
<P>Remote allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-18 13:58:23 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fricke-2008">
<DESCRIPTION>
<P>Remote allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-18 13:36:43 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kellstein-2004">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-18 13:37:18 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zelenakas-2004">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2010-02-18 14:07:19 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-18 14:05:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chan-2005">
<DESCRIPTION>
<P>"double dummy"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-18 13:58:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fricke-2008">
<DESCRIPTION>
<P>"double dummy"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-18 14:02:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kellstein-2004">
<DESCRIPTION>
<P>"double dummy"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-18 14:07:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zelenakas-2004">
<DESCRIPTION>
<P>"double dummy"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-07-29 16:04:58 +0100" MODIFIED_BY="Jessica R Thomas"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2010-03-05 14:22:19 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2010-03-05 14:22:19 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Lumiracoxib versus placebo</NAME>
<DICH_OUTCOME CHI2="21.098838548207404" CI_END="11.508714960632137" CI_START="4.128542900669326" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="6.893056176076375" ESTIMABLE="YES" EVENTS_1="183" EVENTS_2="17" I2="85.78120784636799" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="1.0610268339110542" LOG_CI_START="0.6157968018124336" LOG_EFFECT_SIZE="0.8384118178617439" METHOD="MH" MODIFIED="2010-02-18 14:21:45 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0041612892830454E-4" P_Q="1.0" P_Z="1.5638810817457847E-13" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="367" TOTAL_2="213" WEIGHT="99.99999999999999" Z="7.381608825784618">
<NAME>Participants with at least 50% pain relief at 6 hours</NAME>
<GROUP_LABEL_1>Lumiracoxib 400 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lumiracoxb</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.457966020645626" CI_START="0.9559912110847546" EFFECT_SIZE="1.8181818181818181" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="11" LOG_CI_END="0.5388207214079421" LOG_CI_START="-0.019546100396429893" LOG_EFFECT_SIZE="0.2596373105057561" ORDER="1515" O_E="0.0" SE="0.32798743508823264" STUDY_ID="STD-Chan-2005" TOTAL_1="60" TOTAL_2="60" VAR="0.1075757575757576" WEIGHT="59.75027629505961"/>
<DICH_DATA CI_END="893.0502408748557" CI_START="3.5588483707576244" EFFECT_SIZE="56.37579617834395" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="0" LOG_CI_END="2.950875891946724" LOG_CI_START="0.5513094847315538" LOG_EFFECT_SIZE="1.7510926883391387" MODIFIED="2010-02-18 14:21:03 +0000" MODIFIED_BY="[Empty name]" ORDER="27" O_E="0.0" SE="1.4095171856434732" STUDY_ID="STD-Fricke-2008" TOTAL_1="156" TOTAL_2="52" VAR="1.986738696624297" WEIGHT="4.060949514426129"/>
<DICH_DATA CI_END="785.9957678528433" CI_START="3.111211995995528" EFFECT_SIZE="49.450980392156865" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="0" LOG_CI_END="2.8954202076130655" LOG_CI_START="0.4929296046651872" LOG_EFFECT_SIZE="1.6941749061391265" ORDER="1516" O_E="0.0" SE="1.4112348726918684" STUDY_ID="STD-Kellstein-2004" TOTAL_1="101" TOTAL_2="51" VAR="1.9915838659016343" WEIGHT="3.5977143932090203"/>
<DICH_DATA CI_END="11.621318703231822" CI_START="2.4476090167404334" EFFECT_SIZE="5.333333333333333" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="6" LOG_CI_END="1.0652554114486645" LOG_CI_START="0.38874204442386023" LOG_EFFECT_SIZE="0.7269987279362623" ORDER="1517" O_E="0.0" SE="0.3973873005855455" STUDY_ID="STD-Zelenakas-2004" TOTAL_1="50" TOTAL_2="50" VAR="0.15791666666666668" WEIGHT="32.59105979730524"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.98058054744096" CI_END="0.7656735630623999" CI_START="0.6097607026729273" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6832844574780058" ESTIMABLE="YES" EVENTS_1="169" EVENTS_2="147" I2="74.93916654169581" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.11595634783139691" LOG_CI_START="-0.21484056810156058" LOG_EFFECT_SIZE="-0.16539845796647878" METHOD="MH" MODIFIED="2010-03-05 14:22:19 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.01849439462939162" P_Q="1.0" P_Z="5.502691091996219E-11" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="266" TOTAL_2="162" WEIGHT="100.0" Z="6.5566582782788805">
<NAME>Participants using rescue medication</NAME>
<GROUP_LABEL_1>Lumiracoxib 400 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lumiracoxib</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9366640655948067" CI_START="0.645843364580007" EFFECT_SIZE="0.7777777777777778" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="54" LOG_CI_END="-0.028416140828167163" LOG_CI_START="-0.18987279802196885" LOG_EFFECT_SIZE="-0.10914446942506803" MODIFIED="2010-02-18 14:30:57 +0000" MODIFIED_BY="[Empty name]" ORDER="32" O_E="0.0" SE="0.09484043965898194" STUDY_ID="STD-Chan-2005" TOTAL_1="60" TOTAL_2="60" VAR="0.008994708994708993" WEIGHT="31.671554252199414"/>
<DICH_DATA CI_END="0.8572569017572532" CI_START="0.6468884284330672" EFFECT_SIZE="0.7446808510638298" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="47" LOG_CI_END="-0.06688900970322002" LOG_CI_START="-0.18917061746766367" LOG_EFFECT_SIZE="-0.12802981358544185" MODIFIED="2010-02-18 14:30:57 +0000" MODIFIED_BY="[Empty name]" ORDER="33" O_E="0.0" SE="0.07182882170455486" STUDY_ID="STD-Fricke-2008" TOTAL_1="156" TOTAL_2="52" VAR="0.005159379627464732" WEIGHT="41.348973607038126"/>
<DICH_DATA CI_END="0.6607425622812534" CI_START="0.34617636643167327" EFFECT_SIZE="0.4782608695652174" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="46" LOG_CI_END="-0.17996771685064455" LOG_CI_START="-0.4607025848680911" LOG_EFFECT_SIZE="-0.3203351508593678" MODIFIED="2010-02-18 14:30:57 +0000" MODIFIED_BY="[Empty name]" ORDER="34" O_E="0.0" SE="0.16490505113345696" STUDY_ID="STD-Zelenakas-2004" TOTAL_1="50" TOTAL_2="50" VAR="0.02719367588932806" WEIGHT="26.979472140762464"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.811513498375604" CI_END="1.089060722912722" CI_START="0.423844990098804" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6794063079777366" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="28" I2="65.5855570057778" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.03705209544971745" LOG_CI_START="-0.37279294589183953" LOG_EFFECT_SIZE="-0.167870425221061" METHOD="MH" MODIFIED="2010-03-05 14:22:19 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.05470745645472441" P_Q="1.0" P_Z="0.10836570047307517" Q="0.0" RANDOM="NO" SCALE="15.43314119213444" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="307" TOTAL_2="153" WEIGHT="100.00000000000001" Z="1.6055823753568608">
<NAME>Participants with at least one adverse event</NAME>
<GROUP_LABEL_1>Lumiracoxib 400 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lumiracoxib</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3917579088678198" CI_START="0.31934034045187876" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="9" LOG_CI_END="0.14356369792788418" LOG_CI_START="-0.4957462160392467" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2010-02-18 14:32:26 +0000" MODIFIED_BY="[Empty name]" ORDER="35" O_E="0.0" SE="0.3755338080994054" STUDY_ID="STD-Fricke-2008" TOTAL_1="156" TOTAL_2="52" VAR="0.14102564102564102" WEIGHT="38.07050092764379"/>
<DICH_DATA CI_END="2.3834724558311904" CI_START="0.5824263805394108" EFFECT_SIZE="1.1782178217821782" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="9" LOG_CI_END="0.3772101374463449" LOG_CI_START="-0.2347589622265685" LOG_EFFECT_SIZE="0.07122558760988816" MODIFIED="2010-02-18 14:32:26 +0000" MODIFIED_BY="[Empty name]" ORDER="36" O_E="0.0" SE="0.3594736784437686" STUDY_ID="STD-Kellstein-2004" TOTAL_1="101" TOTAL_2="51" VAR="0.12922132549389392" WEIGHT="33.7291280148423"/>
<DICH_DATA CI_END="0.7522559412382148" CI_START="0.013293347984118263" EFFECT_SIZE="0.1" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="10" LOG_CI_END="-0.12363437356224796" LOG_CI_START="-1.8763656264377517" LOG_EFFECT_SIZE="-1.0" MODIFIED="2010-02-18 14:32:26 +0000" MODIFIED_BY="[Empty name]" ORDER="37" O_E="0.0" SE="1.0295630140987" STUDY_ID="STD-Zelenakas-2004" TOTAL_1="50" TOTAL_2="50" VAR="1.06" WEIGHT="28.20037105751392"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2010-03-05 11:59:26 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2010-03-04 14:44:41 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAACcCAMAAACa91sKAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2010-02-18 14:23:08 +0000" MODIFIED_BY="[Empty name]" NO="2" REF_ID="CMP-001.01" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:YES;SHOW_ROB_TABLE:NO;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Lumiracoxib versus placebo, outcome: 1.1 Participants with at least 50% pain relief at 6 hours.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAzQAAADACAMAAADlR9bXAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Figure 3.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2010-03-05 11:59:26 +0000" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>L'Abbé plot of the four trials, with proportion achieving at least 50% pain relief over six hours with lumiracoxib 400 mg and placebo. The size of the symbol is proportional to the size of the study. Yellow = dental studies, pink = orthopaedic study</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAASgAAAEhCAIAAABDaqqGAAA/PElEQVR42u2dDXwTVbr/gwoCGlFR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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2010-06-03 12:58:31 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2010-03-05 11:49:22 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-11-07 13:09:57 +0000" MODIFIED_BY="Jessica R Thomas">MEDLINE via OVID search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-03-05 11:49:22 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>lumiracoxib or Prexige.mp.</LI>
<LI>Pain, Postoperative/</LI>
<LI>((postoperative adj4 pain*) or (post-operative adj4 pain*) or post-operative-pain* or (post* adj4 pain*) or (postoperative adj4 analgesi*) or (post-operative adj4 analgesi*) or "post-operative analgesi*").mp.</LI>
<LI>((post-surgical adj4 pain*) or ("post surgical" adj4 pain*) or (post-surgery adj4 pain*)).mp.</LI>
<LI>("pain-relief after surg*" or "pain following surg*" or "pain control after").mp.</LI>
<LI>(("post surg*" or post-surg*) and (pain* or discomfort)).mp.</LI>
<LI>((pain* adj4 "after surg*") or (pain* adj4 "after operat*") or (pain* adj4 "follow* operat*") or (pain* adj4 "follow* surg*")).mp.</LI>
<LI>((analgesi* adj4 "after surg*") or (analgesi* adj4 "after operat*") or (analgesi* adj4 "follow* operat*") or (analgesi* adj4 "follow* surg*")).mp.</LI>
<LI>exp Surgical Procedures, Operative/</LI>
<LI>or/2-9</LI>
<LI>randomized controlled trial.pt.</LI>
<LI>controlled clinical trial.pt.</LI>
<LI>randomized.ab.</LI>
<LI>placebo.ab.</LI>
<LI>drug therapy.fs.</LI>
<LI>randomly.ab.</LI>
<LI>trial.ab.</LI>
<LI>groups.ab.</LI>
<LI>or/11-18</LI>
<LI>1 and 10 and 19</LI>
</OL>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2010-03-05 11:54:03 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2010-03-05 11:50:58 +0000" MODIFIED_BY="[Empty name]">EMBASE (via OVID) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-03-05 11:54:03 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Lumiracoxib/</LI>
<LI>(Lumiracoxib or Prexige).mp.</LI>
<LI>OR/1-2</LI>
<LI>Pain, postoperative/</LI>
<LI>((postoperative adj4 pain*) or (post-operative adj4 pain*) or post-operative-pain* or (post* adj4 pain*) or (postoperative adj4 analgesi*) or (post-operative adj4 analgesi*) or ("post-operative analgesi*")).mp. </LI>
<LI>((post-surgical adj4 pain*) or ("post surgical" adj4 pain*) or (post-surgery adj4 pain*)).mp.</LI>
<LI>(("pain-relief after surg*") or ("pain following surg*") or ("pain control after")).mp.</LI>
<LI>(("post surg*" or post-surg*) AND (pain* or discomfort)).mp.</LI>
<LI>((pain* adj4 "after surg*") or (pain* adj4 "after operat*") or (pain* adj4 "follow* operat*") or (pain* adj4 "follow* surg*")).mp.</LI>
<LI>((analgesi* adj4 "after surg*") or (analgesi* adj4 "after operat*") or (analgesi* adj4 "follow* operat*") or (analgesi* adj4 "follow* surg*")).mp.</LI>
<LI>OR/4-10</LI>
<LI>clinical trials.sh.</LI>
<LI>controlled clinical trials.sh.</LI>
<LI>randomized controlled trial.sh.</LI>
<LI>double-blind procedure.sh.</LI>
<LI>(clin* adj25 trial*)</LI>
<LI>((doubl* or trebl* or tripl*) adj25 (blind* or mask*))</LI>
<LI>placebo*</LI>
<LI>random*</LI>
<LI>OR/12-19</LI>
<LI>3 AND 11 AND 20</LI>
</OL>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2010-06-03 12:58:31 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2010-03-05 11:54:48 +0000" MODIFIED_BY="[Empty name]">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-06-03 12:58:31 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>(lumiracoxib or Prexige):ti,ab,kw.</LI>
<LI>MESH descriptor Pain, postoperative</LI>
<LI>((postoperative near/4 pain*) or (post-operative near/4 pain*) or post-operative-pain* or (post* near/4 pain*) or (postoperative near/4 analgesi*) or (post-operative near/4 analgesi*) or ("post-operative analgesi*")):ti,ab,kw.</LI>
<LI>((post-surgical near/4 pain*) or ("post surgical" near/4 pain*) or (post-surgery near/4 pain*)):ti,ab,kw.</LI>
<LI>(("pain-relief after surg*") or ("pain following surg*") or ("pain control after")):ti,ab,kw.</LI>
<LI>(("post surg*" or post-surg*) AND (pain* or discomfort)):ti,ab,kw.</LI>
<LI>((pain* near/4 "after surg*") or (pain* near/4 "after operat*") or (pain* near/4 "follow* operat*") or (pain* near/4 "follow* surg*")):ti,ab,kw.</LI>
<LI>((analgesi* near/4 "after surg*") or (analgesi* near/4 "after operat*") or (analgesi* near/4 "follow$ operat*") or (analgesi* near/4 "follow* surg*")):ti,ab,kw.</LI>
<LI>or/2-8</LI>
<LI>1 AND 9</LI>
<LI>Limit 10 to Clinical Trials (CENTRAL)</LI>
</OL>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2010-02-18 17:17:47 +0000" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2010-02-18 14:35:38 +0000" MODIFIED_BY="[Empty name]">Glossary</TITLE>
<APPENDIX_BODY MODIFIED="2010-02-18 17:17:47 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Categorical rating scale:</B> The commonest is the five category scale (none, slight, moderate, good or lots, and complete). For analysis numbers are given to the verbal categories (for pain intensity, none=0, mild=1, moderate=2 and severe=3, and for relief none=0, slight=1, moderate=2, good or lots=3 and complete=4). Data from different subjects is then combined to produce means (rarely medians) and measures of dispersion (usually standard errors of means). The validity of converting categories into numerical scores was checked by comparison with concurrent visual analogue scale measurements. Good correlation was found, especially between pain relief scales using cross-modality matching techniques. Results are usually reported as continuous data, mean or median pain relief or intensity. Few studies present results as discrete data, giving the number of participants who report a certain level of pain intensity or relief at any given assessment point. The main advantages of the categorical scales are that they are quick and simple. The small number of descriptors may force the scorer to choose a particular category when none describes the pain satisfactorily.</P>
<P>
<B>VAS:</B> Visual analogue scale: lines with left end labelled "no relief of pain" and right end labelled "complete relief of pain", seem to overcome this limitation. Patients mark the line at the point which corresponds to their pain. The scores are obtained by measuring the distance between the no relief end and the patient's mark, usually in millimetres. The main advantages of VAS are that they are simple and quick to score, avoid imprecise descriptive terms and provide many points from which to choose. More concentration and coordination are needed, which can be difficult post-operatively or with neurological disorders.</P>
<P>
<B>TOTPAR:</B> Total pain relief (TOTPAR) is calculated as the sum of pain relief scores over a period of time. If a patient had complete pain relief immediately after taking an analgesic, and maintained that level of pain relief for six hours, they would have a six-hour TOTPAR of the maximum of 24. Differences between pain relief values at the start and end of a measurement period are dealt with by the composite trapezoidal rule. This is a simple method that approximately calculates the definite integral of the area under the pain relief curve by calculating the sum of the areas of several trapezoids that together closely approximate to the area under the curve.</P>
<P>
<B>SPID</B>: Summed pain intensity difference (SPID) is calculated as the sum of the differences between the pain scores over a period of time. Differences between pain intensity values at the start and end of a measurement period are dealt with by the trapezoidal rule.</P>
<P>
<B>VAS TOTPAR and VAS SPID</B> are visual analogue versions of TOTPAR and SPID.</P>
<P>See "Measuring pain" in Bandolier's Little Book of Pain, Oxford University Press, Oxford. 2003; pp 7-13 (<LINK REF="REF-Moore-2003" TYPE="REFERENCE">Moore 2003</LINK>).</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2010-02-18 15:04:30 +0000" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2010-02-18 14:36:30 +0000" MODIFIED_BY="[Empty name]">Summary of efficacy outcomes in individual studies</TITLE>
<APPENDIX_BODY MODIFIED="2010-02-18 15:04:30 +0000" MODIFIED_BY="[Empty name]">
<TABLE COLS="8" ROWS="6">
<TR>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER" COLSPAN="4">
<P>
<B>Analgesia</B>
</P>
</TD>
<TD ALIGN="CENTER" COLSPAN="2">
<P>
<B>Rescue medication</B>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="CENTER">
<P>Study ID</P>
</TH>
<TH ALIGN="CENTER">
<P>Treatment</P>
</TH>
<TH ALIGN="CENTER">
<P>PI or PR</P>
</TH>
<TH ALIGN="CENTER">
<P>Number with 50% PR</P>
</TH>
<TH ALIGN="CENTER">
<P>PGE: excellent</P>
</TH>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>Median time to onset</P>
</TH>
<TH ALIGN="CENTER">
<P>Median time to use (h)</P>
</TH>
<TH ALIGN="CENTER">
<P>% using</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Chan 2005</P>
</TD>
<TD VALIGN="TOP">
<P>(1) lumiracoxib 400 mg, n=60</P>
<P>(2) naproxen 500 mg, n=60</P>
<P>(3) placebo, n=60</P>
</TD>
<TD VALIGN="TOP">
<P>TOTPAR 6:</P>
<P>(1) 8.19</P>
<P>(3) 5.58</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 20/59</P>
<P>(3) 11/59</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 16/60</P>
<P>(3) 1/60</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 0.62</P>
<P>(3) &gt;12</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 3.8</P>
<P>(3) 2.0</P>
</TD>
<TD VALIGN="TOP">
<P>at 12 h:</P>
<P>(1) 42/60</P>
<P>(3) 54/60</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Fricke 2008</P>
</TD>
<TD VALIGN="TOP">
<P>(1) lumiracoxib 400 mg, n = 156</P>
<P>(2) celecoxib 400 mg, n = 156</P>
<P>(3) placebo, n = 52</P>
</TD>
<TD VALIGN="TOP">
<P>TOTPAR 6:</P>
<P>(1) 11.71</P>
<P>(3) 1.79</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 83/156</P>
<P>(3) 0/52</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 45/156</P>
<P>(3) 1/52</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 0.63</P>
<P>(3) not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 12.1</P>
<P>(3) 1.3</P>
</TD>
<TD VALIGN="TOP">
<P>at 24 h:</P>
<P>(1) 105/156</P>
<P>(3) 47/52</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Kellstein 2004</P>
</TD>
<TD VALIGN="TOP">
<P>(1) lumiracoxib 400 mg, n=101</P>
<P>(2) rofecoxib50mg, n=102</P>
<P>(3) celecoxib 200mg, n=101</P>
<P>(4) placebo, n=51</P>
</TD>
<TD VALIGN="TOP">
<P>TOTPAR 6:</P>
<P>(1) 10.68</P>
<P>(4) 1.40</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 48/101</P>
<P>(4) 0/51</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 32/101</P>
<P>(4) 1/51</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 0.66</P>
<P>(4) &gt;12</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 7.2</P>
<P>(4) 1.3</P>
</TD>
<TD VALIGN="TOP">
<P>14.9% of whole group</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Zelenekas 2004</P>
</TD>
<TD VALIGN="TOP">
<P>(1) lumiracoxib 400 mg, n=50</P>
<P>(2) Ibuprofen 400 mg, n=51</P>
<P>(3) placebo, n=50</P>
</TD>
<TD VALIGN="TOP">
<P>TOTPAR 6:</P>
<P>(1) 13.63</P>
<P>(3) 4.16</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 32/50</P>
<P>(3) 6/50</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 23/50</P>
<P>(3) 3/50</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 0.62</P>
<P>(3) &gt;12</P>
</TD>
<TD VALIGN="TOP">
<P>(1) &gt;12</P>
<P>(3) 2</P>
</TD>
<TD VALIGN="TOP">
<P>at 12 h:</P>
<P>(1) 22/50</P>
<P>(3) 46/50</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2010-03-05 11:43:47 +0000" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2010-02-18 14:56:47 +0000" MODIFIED_BY="[Empty name]">Summary of adverse events and withdrawals</TITLE>
<APPENDIX_BODY MODIFIED="2010-03-05 11:43:47 +0000" MODIFIED_BY="[Empty name]">
<TABLE COLS="6" ROWS="6">
<TR>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER" COLSPAN="2">
<P>
<B>Adverse events</B>
</P>
</TD>
<TD ALIGN="CENTER" COLSPAN="2">
<P>
<B>Withdrawals</B>
</P>
</TD>
</TR>
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Any</P>
</TH>
<TH>
<P>Serious</P>
</TH>
<TH>
<P>Adverse event</P>
</TH>
<TH>
<P>Other</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Chan 2005</P>
</TD>
<TD VALIGN="TOP">
<P>(1) lumiracoxib 400 mg, n=60</P>
<P>(2) naproxen 500 mg, n=60</P>
<P>(3) placebo, n=60</P>
</TD>
<TD VALIGN="TOP">
<P>no single dose data</P>
</TD>
<TD VALIGN="TOP">
<P>None</P>
</TD>
<TD VALIGN="TOP">
<P>None</P>
</TD>
<TD VALIGN="TOP">
<P>None</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Fricke 2008</P>
</TD>
<TD VALIGN="TOP">
<P>(1) lumiracoxib 400 mg, n = 156</P>
<P>(2) celecoxib 400 mg, n = 156</P>
<P>(3) placebo, n = 52</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 18/156</P>
<P>(3) 9/52</P>
</TD>
<TD VALIGN="TOP">
<P>None</P>
</TD>
<TD VALIGN="TOP">
<P>None</P>
</TD>
<TD VALIGN="TOP">
<P>None</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Kellstein 2004</P>
</TD>
<TD VALIGN="TOP">
<P>(1) lumiracoxib 400 mg, n=101</P>
<P>(2) rofecoxib50mg, n=102</P>
<P>(3) celecoxib 200mg, n=101</P>
<P>(4) placebo, n=51</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 21/101</P>
<P>(4) 9/51</P>
</TD>
<TD VALIGN="TOP">
<P>None</P>
</TD>
<TD VALIGN="TOP">
<P>None</P>
</TD>
<TD VALIGN="TOP">
<P>None</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Zelenekas 2004</P>
</TD>
<TD VALIGN="TOP">
<P>(1) lumiracoxib 400 mg, n=50</P>
<P>(2) Ibuprofen 400 mg, n=51</P>
<P>(3) placebo, n=50</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 1/50</P>
<P>(3) 10/50</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 0/50</P>
<P>(3) 1/50 (DVT)</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 0/50</P>
<P>(2) 1/51</P>
<P>(3) 0/50 </P>
</TD>
<TD VALIGN="TOP">
<P>None</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>